The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by Mizuho Securities USA LLC

Mizuho Securities USA LLC increased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 270.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,784 shares of the medical device company's stock after acquiring an additional 41,451 shares during the quarter. Mizuho Securities USA LLC's holdings in Cooper Companies were worth $6,266,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. LRI Investments LLC raised its stake in Cooper Companies by 4.5% during the 2nd quarter. LRI Investments LLC now owns 2,595 shares of the medical device company's stock valued at $227,000 after purchasing an additional 112 shares during the last quarter. Mitchell & Pahl Private Wealth LLC grew its holdings in Cooper Companies by 1.5% during the 3rd quarter. Mitchell & Pahl Private Wealth LLC now owns 7,986 shares of the medical device company's stock worth $881,000 after acquiring an additional 117 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Cooper Companies by 0.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 15,600 shares of the medical device company's stock valued at $1,362,000 after purchasing an additional 118 shares during the last quarter. Bleakley Financial Group LLC boosted its stake in shares of Cooper Companies by 2.1% in the 3rd quarter. Bleakley Financial Group LLC now owns 5,767 shares of the medical device company's stock valued at $636,000 after purchasing an additional 119 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its position in shares of Cooper Companies by 4.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,709 shares of the medical device company's stock valued at $236,000 after acquiring an additional 125 shares during the period. Institutional investors and hedge funds own 24.39% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on COO shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a research note on Thursday, August 29th. Wells Fargo & Company lifted their target price on Cooper Companies from $110.00 to $115.00 and gave the stock an "overweight" rating in a report on Thursday, August 29th. Piper Sandler boosted their price target on Cooper Companies from $115.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday, August 29th. Morgan Stanley boosted their price target on Cooper Companies from $95.00 to $104.00 and gave the company an "equal weight" rating in a research note on Tuesday, September 10th. Finally, Robert W. Baird boosted their target price on Cooper Companies from $118.00 to $125.00 and gave the stock an "outperform" rating in a research note on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of "Moderate Buy" and a consensus target price of $117.00.

Cooper Companies Stock Performance

COO traded down $0.23 during midday trading on Friday, reaching $99.63. The company had a trading volume of 1,415,083 shares, compared to its average volume of 1,305,282. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average of $106.83 and a two-hundred day moving average of $98.00. The company has a market cap of $19.84 billion, a P/E ratio of 55.50, a P/E/G ratio of 2.15 and a beta of 0.99. The Cooper Companies, Inc. has a 1 year low of $82.21 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.84 EPS. As a group, equities research analysts predict that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Daniel G. Mcbride sold 114,992 shares of the company's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares of the company's stock, valued at approximately $4,714,534.08. This represents a 72.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Agostino Ricupati sold 1,601 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the sale, the chief accounting officer now owns 4,818 shares of the company's stock, valued at approximately $520,488.54. This trade represents a 24.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock worth $27,637,427 in the last ninety days. 2.00% of the stock is owned by insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.